In the latest trading session,, 0.94 million Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) shares changed hands as the company’s beta touched 0.61. With the company’s most recent per share price at $17.14 changing hands around $0.12 or 0.68% at last look, the market valuation stands at $19.64B. TEVA’s current price is a discount, trading about -33.02% off its 52-week high of $22.80. The share price had its 52-week low at $12.47, which suggests the last value was 27.25% up since then. When we look at Teva- Pharmaceutical Industries Ltd. ADR’s average trading volume, we note the 10-day average is 15.57 million shares, with the 3-month average coming to 12.40 million.
Analysts gave the Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.60. If we narrow down to specifics, the data shows that 1 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TEVA as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
Instantly TEVA is in green as seen in intraday trades today. With action -1.97%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -22.25%, with the 5-day performance at -1.97% in the red. However, in the 30-day time frame, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) is 28.75% up. Looking at the short shares, we see there were 28.43 million shares sold at short interest cover period of 2.31 days.
The consensus price target for the stock as assigned by Wall Street analysts is 28, meaning bulls need an upside of 38.79% from its recent market value. According to analyst projections, TEVA’s forecast low is 28 with 28 as the target high. To hit the forecast high, the stock’s price needs a -63.36% plunge from its current level, while the stock would need to soar -63.36% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -9.62%. The 2025 estimates are for Teva- Pharmaceutical Industries Ltd. ADR earnings to increase by 2.38%, but the outlook for the next 5-year period is at 7.26% per year.
TEVA Dividends
Teva- Pharmaceutical Industries Ltd. ADR is expected to release its next quarterly earnings report on 2025-May-06. During the past 5 years, the average dividend yield was 2.95 per year.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.00% of Teva- Pharmaceutical Industries Ltd. ADR shares while 64.14% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 64.14%. There are 64.14% institutions holding the Teva- Pharmaceutical Industries Ltd. ADR stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 3.7942% of the shares, roughly 42.99 million TEVA shares worth $698.55 million.
FMR LLC holds the second largest percentage of outstanding shares, with 3.7051% or 41.98 million shares worth $682.15 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were Fidelity Contrafund and iShares Trust-iShares Core MSCI EAFE ETF . With 18.74 shares estimated at $318.41 million under it, the former controlled 1.64% of total outstanding shares. On the other hand, iShares Trust-iShares Core MSCI EAFE ETF held about 0.62% of the shares, roughly 7.16 shares worth around $121.69 million.
